✦ LIBER ✦

Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis

✍ Scribed by R Giacchino; G Giambartolomei; L Tasso; A Timitilli; E Castagnola; M Brisigotti; C Micalizzi

Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 149 KB
Volume: 87
Category: Article
ISSN: 0035-9203
DOI: 10.1016/0035-9203(93)90141-c

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful treatment of resistant viscer

Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B

✍ P.C. Gokhale; N.A. Kshirsagar; M.U. Khan; S.K. Pandya; Y.V. Meisheri; C.P. Thaku 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Post-kala-azar dermal leishmaniasis with

Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B

✍ Roustan; JimÉnez; GutiÉrrez-Solar; Gallego; Alvar; PatrÓN 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB

Post-kala-azar dermal leishmaniasis (PKDL) is a rare clinical variant of cutaneous leishmaniasis. It is very common in the Indian subcontinent and less frequent in East Africa, but exceptional in the American and European continents. We have observed a case of PKDL in a renal transplant recipient. N

Apparently successful treatment of two c

Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B

✍ F.A. Hashim; E.A.G. Khalil; A. Ismail; A.M.El Hassan 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Amphotericin B deoxycholate treatment of

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

✍ C.P. Thakur; R.K. Singh; S.M. Hassan; R. Kumar; S. Narain; Ashok Kumar 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 747 KB

Out of 938 parasitologically confirmed patients with visceral leishmaniasis treated with amphotericin B (1 mg/kg bodyweight daily infused in 2 h for 20 days), 935 were cured clinically, 933 parasitologically and 931 ultimately (no relapse within 6 months). Two parasitologically 'not cured' and 4 rel

Efficacy and toxicity of caspofungin in

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

✍ Dimitrios P. Kontoyiannis; Ray Hachem; Russell E. Lewis; Gustavo A. Rivero; Harr 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Caspofungin (CAS) as salvage therapy for refractory invasive aspergillosis (IA) had a response rate of 45% among a heterogeneous group of patients. The use of CAS with other agents is appealing given its unique mechanism of action. Therefore, the authors retrospectively e